SCHEDULE 13G
Under the Securities Exchange Act of 1934
Agile Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00847L100
(CUSIP Number)
January 22, 2016
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
* | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| | | | | | |
1 | | NAMES OF REPORTING PERSONS Vivo Capital VIII, LLC |
2 | | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) ¨ |
3 | | SEC USE ONLY |
4 | | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | | 5 | | SOLE VOTING POWER 1,702,439(1) |
| 6 | | SHARED VOTING POWER 0 |
| 7 | | SOLE DISPOSITIVE POWER 1,702,439(1) |
| 8 | | SHARED DISPOSITIVE POWER 0 |
9 | | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,702,439(1) |
10 | | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨ |
11 | | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.6%(2) |
12 | | TYPE OF REPORTING PERSON (See Instructions) OO |
(1) | The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., and Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. |
(2) | Based on 22,292,167 shares of common stock outstanding as of shares outstanding as of November 9, 2015, as reported in the issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2015, filed on November 9, 2015. |
ITEM 1. (a) | NAMEOF ISSUER: |
Agile Therapeutics, Inc.
| (b) | ADDRESSOF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: |
101 Poor Farm Road, Princeton, New Jersey 08540
ITEM 2. (a) | NAMEOF PERSON FILING: |
Vivo Capital VIII, LLC
| (b) | ADDRESSOF PRINCIPAL BUSINESS OFFICEOR,IF NONE, RESIDENCE: |
575 High Street, Suite 201, Palo Alto, CA 94301
Vivo Capital VIII, LLC, is a Delaware limited liability company.
| (d) | TITLEOF CLASSOF SECURITIES: |
Common Stock
00847L100
ITEM 3. | IF THIS STATEMENTIS FILED PURSUANTTO §§ 240.13d-1(b),OR 240.13d-2(b)OR (c), CHECK WHETHERTHE PERSON FILINGISA: |
| | | | | | |
| | (a) | | ¨ | | Broker or dealer registered under Section 15 of the Act. |
| | | |
| | (b) | | ¨ | | Bank as defined in Section 3(a)(6) of the Act. |
| | | |
| | (c) | | ¨ | | Insurance company as defined in Section 3(a)(19) of the Act. |
| | | |
| | (d) | | ¨ | | Investment company registered under Section 8 of the Investment Company Act of 1940. |
| | | |
| | (e) | | ¨ | | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
| | | |
| | (f) | | ¨ | | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
| | | |
| | (g) | | ¨ | | A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G); |
| | | |
| | (h) | | ¨ | | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; |
| | | |
| | (i) | | ¨ | | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; |
| | | |
| | (j) | | ¨ | | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); |
| | | |
| | (k) | | ¨ | | Group, in accordance with § 240.13d-1(b)(l)(ii)(K). |
If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution:
Not Applicable.
| (a) | AMOUNTBENEFICIALLYOWNED: |
The shares of common stock are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.:
| • | | Vivo Capital Fund VIII, L.P.: 1,495,875 shares |
| • | | Vivo Capital Surplus Fund VIII, L.P.: 206,564 shares |
Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. The voting members of Vivo Capital VIII, LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.
7.6% (based on 22,292,167 shares of common stock outstanding as of shares outstanding as of November 9, 2015, as reported in the issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2015, filed on November 9, 2015).
| (c) | NUMBEROFSHARESASTOWHICHSUCHPERSONHAS: |
| (i) | Sole power to vote or to direct the vote: 1,702,439 |
| (ii) | Shared power to vote or to direct the vote: 0 |
| (iii) | Sole power to dispose or to direct the disposition of: 1,702,439 |
| (iv) | Shared power to dispose of or to direct the disposition of: 0 |
ITEM 5. | OWNERSHIPOF FIVE PERCENTOR LESSOFA CLASS. |
Not Applicable.
ITEM 6. | OWNERSHIPOF MORETHAN FIVE PERCENTON BEHALFOF ANOTHER PERSON. |
Not Applicable.
ITEM 7. | IDENTIFICATIONAND CLASSIFICATIONOFTHE SUBSIDIARY WHICH ACQUIREDTHE SECURITY BEING REPORTEDONBYTHE PARENT HOLDING COMPANYOR CONTROL PERSON. |
Not Applicable.
ITEM 8. | IDENTIFICATIONAND CLASSIFICATIONOF MEMBERSOFTHE GROUP. |
Not applicable.
ITEM 9. | NOTICEOF DISSOLUTIONOF GROUP. |
Not applicable.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Vivo Capital VIII, LLC |
|
January 29, 2016 |
(Date) |
|
/s/ Albert Cha |
(Signature) |
|
Managing Member |
(Title) |